NUREXONE BIOLOGIC INC. (J90) — Financial Flexibility Index
NUREXONE BIOLOGIC INC. (J90) has a Financial Flexibility Index of -0.88x as of December 2025. Free cash flow of €-1.17 Million (operating CF €-1.17 Million minus capex €9.00K) represents -1% of total liabilities (€1.32 Million). Also explore net asset momentum of NUREXONE BIOLOGIC INC. to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NUREXONE BIOLOGIC INC. Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for NUREXONE BIOLOGIC INC. across 5 annual periods. See NUREXONE BIOLOGIC INC. balance sheet quality to measure how much of total assets are equity-financed.
Annual Financial Flexibility Index for NUREXONE BIOLOGIC INC. (2021–2025)
Year-by-year free cash flow to debt coverage for NUREXONE BIOLOGIC INC.. For the full company profile including market capitalisation, see NUREXONE BIOLOGIC INC. (J90) total market value.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.36x | €-4.46 Million | €-4.51 Million | €1.32 Million | ▲ +46.1% |
| 2024 | -6.23x | €-4.24 Million | €-4.89 Million | €680.00K | ▼ -337.8% |
| 2023 | -1.42x | €-2.82 Million | €-2.94 Million | €1.98 Million | ▲ +73.8% |
| 2022 | -5.44x | €-3.80 Million | €-3.85 Million | €698.00K | ▼ -632.3% |
| 2021 | -0.74x | €-1.23 Million | €-1.23 Million | €1.66 Million | — |